- Home
- LAC vs DCTH Comparison
LAC vs DCTH Comparison
Compare LAC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAC
- DCTH
- Stock Information
- Founded
- LAC 2023
- DCTH 1988
- Country
- LAC Canada
- DCTH United States
- Employees
- LAC N/A
- DCTH N/A
- Industry
- LAC Metal Mining
- DCTH Medical/Dental Instruments
- Sector
- LAC Basic Materials
- DCTH Health Care
- Exchange
- LAC Nasdaq
- DCTH Nasdaq
- Market Cap
- LAC 617.3M
- DCTH 630.4M
- IPO Year
- LAC N/A
- DCTH N/A
- Fundamental
- Price
- LAC $2.68
- DCTH $16.21
- Analyst Decision
- LAC Hold
- DCTH Strong Buy
- Analyst Count
- LAC 6
- DCTH 4
- Target Price
- LAC $4.29
- DCTH $24.00
- AVG Volume (30 Days)
- LAC 4.6M
- DCTH 610.5K
- Earning Date
- LAC 05-15-2025
- DCTH 05-08-2025
- Dividend Yield
- LAC N/A
- DCTH N/A
- EPS Growth
- LAC N/A
- DCTH N/A
- EPS
- LAC N/A
- DCTH N/A
- Revenue
- LAC N/A
- DCTH $53,850,000.00
- Revenue This Year
- LAC N/A
- DCTH $141.47
- Revenue Next Year
- LAC N/A
- DCTH $49.31
- P/E Ratio
- LAC N/A
- DCTH N/A
- Revenue Growth
- LAC N/A
- DCTH 1068.87
- 52 Week Low
- LAC $2.02
- DCTH $6.33
- 52 Week High
- LAC $5.20
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- LAC 39.68
- DCTH 58.15
- Support Level
- LAC $2.66
- DCTH $16.02
- Resistance Level
- LAC $2.81
- DCTH $17.29
- Average True Range (ATR)
- LAC 0.14
- DCTH 0.99
- MACD
- LAC -0.04
- DCTH -0.03
- Stochastic Oscillator
- LAC 7.97
- DCTH 49.63
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, that is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass recently began construction and is expected to begin production in the late 2020s. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.